MA52691A - Compositions à base de statine et procédés destinés à être utilisés dans le traitement de synucléinopathies - Google Patents

Compositions à base de statine et procédés destinés à être utilisés dans le traitement de synucléinopathies

Info

Publication number
MA52691A
MA52691A MA052691A MA52691A MA52691A MA 52691 A MA52691 A MA 52691A MA 052691 A MA052691 A MA 052691A MA 52691 A MA52691 A MA 52691A MA 52691 A MA52691 A MA 52691A
Authority
MA
Morocco
Prior art keywords
synucleinopathies
treatment
methods
statin compositions
statin
Prior art date
Application number
MA052691A
Other languages
English (en)
Inventor
Thomas N Chase
Kathleen E Clarence-Smith
Original Assignee
Chase Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chase Therapeutics Corp filed Critical Chase Therapeutics Corp
Publication of MA52691A publication Critical patent/MA52691A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA052691A 2017-07-03 2018-07-03 Compositions à base de statine et procédés destinés à être utilisés dans le traitement de synucléinopathies MA52691A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762528204P 2017-07-03 2017-07-03

Publications (1)

Publication Number Publication Date
MA52691A true MA52691A (fr) 2021-03-31

Family

ID=64950317

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052691A MA52691A (fr) 2017-07-03 2018-07-03 Compositions à base de statine et procédés destinés à être utilisés dans le traitement de synucléinopathies

Country Status (14)

Country Link
US (1) US20200113899A1 (fr)
EP (1) EP3648756A4 (fr)
JP (1) JP2020526487A (fr)
KR (1) KR20200026925A (fr)
CN (1) CN111093647A (fr)
AU (1) AU2018298012A1 (fr)
BR (1) BR112020000021A2 (fr)
CA (1) CA3105337A1 (fr)
EA (1) EA202090194A1 (fr)
IL (1) IL271758A (fr)
MA (1) MA52691A (fr)
MX (1) MX2019015280A (fr)
TW (1) TW201906605A (fr)
WO (1) WO2019010146A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12502370B2 (en) * 2019-04-11 2025-12-23 Cmpd Licensing, Llc Wound treatments and compositions
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US12156875B2 (en) 2019-04-11 2024-12-03 Cmpd Licensing, Llc Wound treatments and compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109990A2 (fr) * 2008-01-24 2009-09-11 Sun Pharmaceutical Industries Ltd. Composition pharmaceutique de pramipexole
WO2010010136A1 (fr) * 2008-07-24 2010-01-28 Boehringer Ingelheim International Gmbh Composition pharmaceutique contenant du pramipexole et un agent anti-inflammatoire destinée au traitement de la maladie de parkinson
MX2016002178A (es) * 2013-08-21 2016-06-06 Resverlogix Corp Composiciones y metodos terapeuticos para la regresion acelerada de placa.

Also Published As

Publication number Publication date
MX2019015280A (es) 2020-08-17
EP3648756A1 (fr) 2020-05-13
KR20200026925A (ko) 2020-03-11
IL271758A (en) 2020-02-27
US20200113899A1 (en) 2020-04-16
CN111093647A (zh) 2020-05-01
BR112020000021A2 (pt) 2020-07-21
AU2018298012A1 (en) 2020-02-13
CA3105337A1 (fr) 2019-01-10
JP2020526487A (ja) 2020-08-31
EP3648756A4 (fr) 2021-03-31
TW201906605A (zh) 2019-02-16
WO2019010146A1 (fr) 2019-01-10
EA202090194A1 (ru) 2020-05-27

Similar Documents

Publication Publication Date Title
EP3377042A4 (fr) Substances et procédés de traitement de myopathies à base de titine et d'autres titinopathies
EP3645739A4 (fr) Procédés et compositions pour le traitement du mélanome
MA45290A (fr) Procédés et compositions d'agents biologiquement actifs
EP3704239A4 (fr) Compositions de casz et procédés d'utilisation
MA45270A (fr) Compositions d'oligonucléotides et procédés associés
EP3630072A4 (fr) Procédés et compositions pour le traitement d'une somnolence excessive
FR24C1010I2 (fr) Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux
EP3634430A4 (fr) Agents multibiotiques et procédés d'utilisation de ceux-ci
MA52691A (fr) Compositions à base de statine et procédés destinés à être utilisés dans le traitement de synucléinopathies
MA47688A (fr) Compositions utiles dans le traitement de l'amyotrophie spinale
MA71705A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
EP3612215A4 (fr) Compositions et procédés pour le traitement d'inflammation pulmonaire
MA45688A (fr) Compositions et procédés de potentialisation d'agents antimicrobiens
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA46427A (fr) Compositions d'oligonucléotides et procédés associés
EP3341391A4 (fr) Compositions et procédés pour le traitement de la douleur
EP3735325A4 (fr) Compositions et procédés de traitement de surface
EP3390642A4 (fr) Compositions et procédés pour le traitement de rétinite pigmentaire 18 et de rétinite pigmentaire 13
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
EP3833340A4 (fr) Compositions et procédés de traitement de la presbytie
EP3448421A4 (fr) Procédés et compositions pour la prévention et le traitement d'adhérences chirurgicales
MA49248A (fr) Inhibiteurs de fgfr2 utilisés dans le traitement du cholangiocarcinome
MA49524A (fr) Compositions d'antagoniste de nk-1 et méthodes destinées à être utilisées dans le traitement de la dépression
MA50905A (fr) Composés et compositions pharmaceutiques de ceux-ci destinés à être utilisés dans le traitement de maladies fibrotiques
EP3413887A4 (fr) Intermédiaires utilisés dans la synthèse d'éribuline et procédés de synthèse associés